EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bioequivalence Evaluation of Immediate-Release Empagliflozin/Metformin Fixed-Dose Combination Tablets Under Fed Conditions in Healthy Mexican Subjects and Exploratory Analysis of Metformin Dose Proportionality

Erika Gabriela Guido Ávila, Alberto Martínez Muñoz, Porfirio de la Cruz Cruz, Omar Emmanuel Hernández Piña, José Trinidad Pérez-Urizar iD, Abraham Escobedo-Moratilla iD

Pharmaceuticals · 31.07.2026 · 19 (8) · 1200

DOI: 10.3390/ph19081200 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 31.07.2026. Verfasst von Erika Gabriela Guido Ávila und 5 weiteren Autor:innen. Beteiligte Einrichtung: Asofarma de México S.A. de C.V., Av. Santa Fe 485, Lomas de Santa Fe, Contadero, Cuajimalpa de Morelos, Ciudad de México 05348, Mexico. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Asofarma de México S.A. de C.V..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Fixed-dose combinations (FDCs) improve therapeutic adherence in type 2 diabetes. These studies aimed to evaluate the pharmacokinetics and establish the bioequivalence of four immediate-release empagliflozin/metformin FDC formulations under fed conditions in healthy Mexican subjects.

Methods

A total of 42 healthy volunteers per study (168 total) were enrolled in four randomized, open-label, two-way crossover, single-dose studies with a 14-day washout period. Formulations were administered orally under standardized fed conditions. Plasma concentrations of both drugs were quantified using a validated liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method.

Results

Across all dose strengths, the 90% confidence intervals (CIs) for the geometric mean ratios of peak plasma concentration (Cmax) and area under the concentration–time curve (AUC0-t) for both empagliflozin and metformin were entirely within the 80.00–125.00% bioequivalence acceptance range. The specific 90% CIs for Cmax and AUC0-t were: Study A (5/850 mg): empagliflozin (90.18–103.16%; 94.37–101.81%), metformin (98.43–107.69%; 97.18–106.62%); Study B (12.5/500 mg): empagliflozin (91.94–102.77%; 93.38–98.51%), metformin (92.58–101.73%; 94.85–103.91%); Study C (12.5/850 mg): empagliflozin (95.47–107.74%; 95.34–101.25%), metformin (94.19–103.59%; 94.06–103.21%); and Study D (12.5/1000 mg): empagliflozin (94.53–107.10%; 98.13–105.66%), metformin (98.89–107.51%; 99.25–109.92%). Regarding safety, no serious adverse events occurred, and all reported events were mild or moderate and resolved completely.

Conclusions

All evaluated empagliflozin/metformin FDCs successfully demonstrated bioequivalence and a favorable safety profile under fed conditions. These findings fulfill regulatory requirements and support their therapeutic interchangeability in clinical practice. An exploratory power-model analysis indicated a modest trend toward less-than-dose-proportional metformin exposure across the 500–1000 mg range (slope β ≈ 0.77–0.78). NCT07633015, NCT07633054, NCT07633028, and NCT07633041.

Schlagwörter

Stichwörter der Autor:innen

bioequivalenceempagliflozinmetforminpharmacokineticstype 2 diabetes

Autor:innen und Institutionen

  • Asofarma de México S.A. de C.V., Av. Santa Fe 485, Lomas de Santa Fe, Contadero, Cuajimalpa de Morelos, Ciudad de México 05348, Mexico.
  • FS Scientia Pharma S.A. de C.V (Authorized Third Party), Av. Himno Nacional 1330, Jardín, San Luis Potosí 78270, Mexico.
  • Doctorado Institucional en Ingeniería y Ciencia de Materiales (DICIM) de la Universidad Autónoma de San Luis Potosí (UASLP), Av. Sierra Leona No. 550, Col. Lomas 2da. Sección, San Luis Potosí 78210, Mexico.
  • Facultad de Ciencias Químicas de la Universidad Autónoma de San Luis Potosí, Av. Dr. Nava No. 6, Zona Universitaria, San Luis Potosí 78210, Mexico.

ORCID-Profile: José Trinidad Pérez-Urizar, Abraham Escobedo-Moratilla

Förderung

  • Asofarma de México S.A. de C.V.

Zitieren

APA

Guido Ávila, E. G., Martínez Muñoz, A., de la Cruz Cruz, P., Hernández Piña, O. E., Pérez-Urizar, J. T., & Escobedo-Moratilla, A. (2026). Bioequivalence Evaluation of Immediate-Release Empagliflozin/Metformin Fixed-Dose Combination Tablets Under Fed Conditions in Healthy Mexican Subjects and Exploratory Analysis of Metformin Dose Proportionality. Pharmaceuticals, 19(8), 1200. https://doi.org/10.3390/ph19081200

Vancouver

Guido Ávila EG, Martínez Muñoz A, de la Cruz Cruz P, Hernández Piña OE, Pérez-Urizar JT, Escobedo-Moratilla A. Bioequivalence Evaluation of Immediate-Release Empagliflozin/Metformin Fixed-Dose Combination Tablets Under Fed Conditions in Healthy Mexican Subjects and Exploratory Analysis of Metformin Dose Proportionality. Pharmaceuticals. 2026;19(8):1200. doi:10.3390/ph19081200

BibTeX
@article{Guidovila2026,
  author = {Guido Ávila, Erika Gabriela and Martínez Muñoz, Alberto and de la Cruz Cruz, Porfirio and Hernández Piña, Omar Emmanuel and Pérez-Urizar, José Trinidad and Escobedo-Moratilla, Abraham},
  title = {Bioequivalence Evaluation of Immediate-Release Empagliflozin/Metformin Fixed-Dose Combination Tablets Under Fed Conditions in Healthy Mexican Subjects and Exploratory Analysis of Metformin Dose Proportionality},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {8},
  pages = {1200},
  doi = {10.3390/ph19081200}
}
Kostenlos starten →